PER® Postgame™: MS Meeting Updates – Integrating the Latest Data to Optimize Care in the COVID-19 Era
Released On
December 20, 2022
Expires On
December 20, 2023
Media Type
Internet
Completion Time
120 minutes
Specialty
Neurology
Topic(s)
Multiple Sclerosis
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Genentech, Inc.
Credit Available
- Physicians — maximum of 2.0 AMA PRA Category 1 Credits™
- Nurses — 2.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward MS specialists, community neurologists, neuroimmunologists, specialty NPs, PAs, RNs, and other members of the MS care team.
Activity Overview
Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS) characterized by demyelination and neurodegenerative progression. Most MS therapies target various immune cells involved in the inflammatory cascade. The recent COVID-19 pandemic has created additional concerns for patients with MS who may be exposed to the causative agent of COVID-19 or develop this potentially life-threatening disease. COVID-19 vaccination is recommended for MS patients; however, questions have been raised about vaccine safety and efficacy in patients with immune-mediated conditions such as MS and the impact of immunosuppressive or immunomodulatory disease-modifying therapies (DMTs).
The PER® Postgame™ is an innovative and unique online activity by PER®. It is an in-depth, engaging data recap program focusing on novel therapeutic agents and emerging treatment strategies discussed at major medical meetings. This program focuses on abstracts presented at the 2022 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and Consortium of Multiple Sclerosis Centers (CMSC) annual meetings.
Learning Objectives
- Upon successful completion of this activity, you should be better prepared to:
-
- Describe currently available molecular biomarkers/other key indicators of MS and their role in early differential diagnosis and monitoring disease progression
- Evaluate recent efficacy and safety data of current and emerging DMTs for the optimal treatment of patients with MS
- Discuss the impact of DMTs on anti-SARS-CoV-2 vaccine response in patients with MS
- Implement timely, evidence-based strategies to maximize immune response to anti-SARS-CoV-2 immunotherapy in patients with MS exposed or infected with SARS-CoV-2
- Design COVID-19 prevention/treatment plans that minimize risk of SARS-CoV-2 infection while maintaining efficacy of DMTs in patients with MS
Faculty
Erin E. Longbrake, MD, PhD
Assistant Professor
Department of Neurology
Yale University
New Haven, CT
Ilya Kister, MD, FAAN
Professor, Department of Neurology
Director, Multiple Sclerosis Fellowship
NYU Grossman School of Medicine
Director, Neuromyelitis Optica Treatment and Research Program
NYU Langone Medical Center
New York, NY
Joseph J. Sabatino Jr, MD, PhD
Assistant Professor
Department of Neurology
Weill Institute for Neurosciences
University of California, San Francisco
San Francisco, CA
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Erin E. Longbrake, MD, PhD
-
- Grant/Research Support: Genentech, Biogen
- Consultant: NGM Bio, Genzyme, EMD Serono, Bristol Myers Squibb, TG Therapeutics, Janssen, Biogen, Genentech
- Ilya Kister, MD, FAAN
-
- Grant/Research Support: Genentech, Sanofi Genzyme, Biogen, EMD Serono
- Consultant: Roche, Biogen, Genentech, Horizon, Alexion
- Other: Received royalties from Walters-Kluwer “Top 100 Diagnosis in Neurology.”
- Joseph J. Sabatino Jr, MD, PhD
-
- Grant/Research Support: Novartis Pharmaceuticals, Roche-Genentech
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.